Arcturus Therapeutics Holdings Inc. ARCT
13.85
(0.27)
(1.91%)
as of 25 Sep
- Market cap
- $412.4M
- P/E
- 0.0×
Follow ARCT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.13 | 2.05 | 4.01 | 6.50 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(29.22) | (10.35) | (11.29) | (9.59) | |
P/B ratio |
2.23 | 0.78 | 1.15 | 1.11 | |
Price to Tangible BV |
2.23 | 0.78 | 1.15 | 1.11 | |
EV/Sales |
2.92 | (0.53) | 0.50 | 0.64 | |
EV/EBITDA |
0.00 | 0.60 | 0.00 | 0.00 | |
EV/Operating CF |
(4.88) | 0.59 | (0.46) | (0.26) | |
EV/FCF |
(4.86) | 0.59 | (0.46) | (0.26) | |
Quick Ratio |
7.68 | 6.50 | 6.19 | 5.76 | |
Current Ratio |
7.86 | 6.64 | 6.31 | 5.88 | |
Net Debt/EBITDA |
14.94 | 7.54 | 7.48 | 7.69 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.30 | 0.27 | 0.19 | 0.11 | |
Operating CF/Net income |
1.28 | 0.56 | 0.72 | 0.84 | |
Capex/Depreciation |
(0.24) | 0.13 | 0.05 | 0.03 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
135.65% | 340.07% | 1,044.49% | 591.92% | |
Selling, General and Administrative Expense of Revenue |
60.63% | 194.91% | 459.24% | 371.38% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
33.40% | 94.72% | 209.85% | 142.99% | |
Graham Net Nets |
0.38 | 1.10 | 0.74 | 0.76 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.35%) | (38.83%) | (36.40%) | (49.26%) | |
Free Cash Flow Yield |
(11.70%) | (44.38%) | (26.72%) | (38.10%) | |
Revenue per Share |
0.63 | 0.26 | 0.07 | 0.10 | |
Operating CF per Share |
(0.63) | (0.59) | (0.68) | (0.70) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.64) | (0.59) | (0.68) | (0.70) | |
Cash per Share |
8.66 | 8.43 | 7.44 | 6.74 | |
Shareholders Equity per Share |
8.26 | 7.81 | 6.73 | 6.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.26 | 7.81 | 6.73 | 6.04 | |
Free Cash Flow |
(17.33) | (16.14) | (19.41) | (19.89) | |
Working Capital |
217.50 | 205.07 | 182.51 | 163.63 | |
Capital Expenditures |
(0.18) | 0.09 | 0.03 | 0.02 | |
Net Current Asset Value |
191.42 | 184.28 | 162.83 | 144.66 | |
EV/EBIT |
0.00 | 0.57 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | (0.01) | (0.02) | (0.01) | |
Net Profit Margin |
(78.41%) | (404.04%) | (1,308.30%) | (803.82%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
19.08 | 4.77 | 7.96 | 9.51 | |
Average Payables |
7.81 | 5.71 | 5.14 | 7.52 | |
Average Assets |
326.50 | 307.61 | 288.60 | 266.79 | |
Average Common Equity |
243.21 | 227.48 | 212.56 | 201.43 |
Columns are period end dates